- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aurinia Pharmaceuticals Inc (AUPH)
Assess today's live Aurinia Pharmaceuticals Inc (AUPH) share price, performance and insights using our live NASDAQ: AUPH stock exchange data.
Analyse the historical data and Aurinia Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Aurinia Pharma share price buy/sell indicators using real-time data (or discuss the Aurinia Pharma (AUPH) stock price today with other investors in the Aurinia Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AUPH share price (ISIN: CA05156V1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Aurinia Pharmaceuticals Inc Share Price Today?
The Aurinia Pharma share price today is 15.280.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc
The stock symbol (or 'ticker') for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Aurinia Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Aurinia Pharma share price buy/sell indicators using real-time data (or discuss the Aurinia Pharma (AUPH) stock price today with other investors in the Aurinia Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AUPH share price (ISIN: CA05156V1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Aurinia Pharmaceuticals Inc Share Price Today?
The Aurinia Pharma share price today is 15.280.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc
The stock symbol (or 'ticker') for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.200
16.010
52 wk Range
7.285
16.880
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.20016.010
52 wk Range
7.28516.880
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AUPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
17.000
Upside
+11.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Q4 EPS of $1.53 vastly exceeded forecast of $0.15 (920% beat); revenue rose 29% YoY to $77.1M, surpassing estimates of $74.41M.
- LUPKYNIS drove 95.7% of revenue; net income surged to $210.8M from $1.4M YoY, boosted by deferred tax asset valuation allowance release.
- Company projects 2026 LUPKYNIS sales of $305-315M (12-16% growth); advancing Aritinercept biologic for autoimmune disease treatment.
- Strong balance sheet with 5.76 current ratio, 80% gross margin, and $45.7M operating cash flow (up 52% YoY); stock rose 3.67% pre-market.
- Key risk: 95.7% revenue concentration in single product exposes company to market shifts, regulatory challenges, and emerging competition.
Last Updated: 26/02/2026, 14:34
Read Full TranscriptCompare AUPH to Peers and Sector
Metrics to compare | AUPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 6.9x | 16.8x | −0.5x | |
PEG Ratio | 0.00 | 0.29 | 0.00 | |
Price/Book | 3.4x | 4.3x | 2.6x | |
Price / LTM Sales | 7.0x | 4.8x | 3.2x | |
Upside (Analyst Target) | 6.0% | 249.4% | 50.8% | |
Fair Value Upside | Unlock | 17.7% | 7.7% | Unlock |
Analyst Ratings
4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.000
(+11.26% Upside)
Earnings
Latest Release
26/02/2026
EPS / Forecast
1.53 / 0.15
Revenue / Forecast
77.1M / 74.41M
People Also Watch
FAQ
What Is the Aurinia Pharma (NASDAQ: AUPH) Share Price Today?
The Aurinia Pharma stock price today is 15.280 USD.
What Stock Exchange Does Aurinia Pharma (AUPH) Trade On?
Aurinia Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Aurinia Pharma?
The stock symbol (also called a 'ticker') for Aurinia Pharma is "AUPH."
What Is the Current Aurinia Pharma Market Capitalisation?
As of today, Aurinia Pharma (NASDAQ: AUPH) market cap is 1.990B USD.
What Is Aurinia Pharma's (AUPH) Earnings Per Share (TTM)?
The Aurinia Pharma EPS is currently 2.070 (Trailing Twelve Months).
When Is the Next Aurinia Pharma Earnings Date?
Aurinia Pharma's next earnings report will be released on 30/04/2026.
Is AUPH a Buy or Sell From a Technical Analyst Perspective?
Based on today's Aurinia Pharma moving averages and other technical indicators, the daily buy/sell signal for AUPH stock is Strong Sell.
How Many Times Has Aurinia Pharma Stock Split?
Aurinia Pharma has split 1 times. (See the AUPH stock split history page for full effective split date and price information.)
How Many Employees Does Aurinia Pharma Have?
Aurinia Pharma has 128 employees, based on their latest Companies House report.
What is the current trading status of Aurinia Pharma (NASDAQ: AUPH)?
As of 30/04/2026, Aurinia Pharma (AUPH) is trading at a share price of 15.280 USD, with a previous close of 16.040 USD. The stock has fluctuated within a day range of 15.200 USD to 16.010 USD, while its 52-week range spans from 7.285 USD to 16.880 USD.
What Is Aurinia Pharma (AUPH) Price Target According to Analysts?
The average 12-month price target for Aurinia Pharma is 17.000 USD, with a high estimate of 21 USD and a low estimate of 15 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +11.26% Upside potential.
What Is the AUPH Premarket Price?
AUPH's last pre-market stock price is 16.270 USD. The pre-market share volume is 36,370.000, and the stock has decreased by 0.230, or 1.430%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.